Publications

Export 1738 results:
Sort by: Author [ Title (Asc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
(
Clark RD, Repke DB, Kilpatrick AT, Brown CM, Mackinnon AC, Clague RU, et al. (8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist. J Med Chem. 1989;32(9):2034-6.
1
O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Annals of neurology. 2006;59:467-77. Abstract
Clark RD, Weinhardt KK, Berger J, Fisher LE, Brown CM, Mackinnon AC, et al. 1,9-Alkano-bridged 2,3,4,5-tetrahydro-1H-3-benzazepines with affinity for the alpha 2-adrenoceptor and the 5-HT1A receptor. J Med Chem. 1990;33(2):633-41. Abstract
Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology. 1995;136(11):4754-61. Abstract
Voice MW, Seckl JR, Edwards CR, Chapman KE. 11 beta-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochem J. 1996;317 ( Pt 2):621-5. Abstract
Wake DJ, Walker BR. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Molecular and cellular endocrinology. 2004;215:45-54. Abstract
Densmore VS, Morton NM, Mullins JJ, Seckl JR. 11 beta-hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-fat feeding: A novel constraint to hyperphagia? Endocrinology. 2006;147:4486-95. Abstract
Jamieson PM, Walker BR, Chapman KE, Andrew R, Rossiter S, Seckl JR. 11 beta-hydroxysteroid dehydrogenase type 1 is a predominant 11 beta-reductase in the intact perfused rat liver. The Journal of endocrinology. 2000;165:685-92. Abstract
Robson AC, Leckie CM, Seckl JR, Holmes MC. 11 Beta-hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Brain research. Molecular brain research. 1998;61:1-10. Abstract
Holmes MC, Yau JL, Kotelevtsev Y, Mullins JJ, Seckl JR. 11 Beta-hydroxysteroid dehydrogenases in the brain: two enzymes two roles. Annals of the New York Academy of Sciences. 2003;1007:357-66. Abstract
Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs. 2008;17(4):481-96. Abstract
Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care. 2010;33(7):1516-22. Abstract
Chapman KE, Seckl JR. 11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function. Neurochem Res. 2008;33(4):624-36. Abstract
Napolitano A, Voice MW, Edwards CR, Seckl JR, Chapman KE. 11Beta-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. The Journal of steroid biochemistry and molecular biology. 1998;64:251-60. Abstract
Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, et al. 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:6734-9. Abstract
Guilding C, Seckl JR, Dutia MB. 11Beta-hydroxysteroid dehydrogenase type 1 activity in medial vestibular nucleus and cerebellum after unilateral vestibular deafferentation in the rat. Stress (Amsterdam, Netherlands). 2004;7:127-30. Abstract
Seckl JR, Walker BR. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends in endocrinology and metabolism: TEM. 2004;15:418-24. Abstract
Walker BR, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert opinion on therapeutic targets. 2003;7:771-83. Abstract
Yau JL, Noble J, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 deficiency prevents memory deficits with aging by switching from glucocorticoid receptor to mineralocorticoid receptor-mediated cognitive control. J Neurosci. 2011;31(11):4188-93. Abstract
Holmes MC, Carter RN, Noble J, Chitnis S, Dutia A, Paterson JM, et al. 11beta-hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments. J Neurosci. 2010;30(20):6916-20. Abstract
Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:14924-9. Abstract
Chapman KE, Gilmour JS, Coutinho AE, Savill JS, Seckl JR. 11Beta-hydroxysteroid dehydrogenase type 1--a role in inflammation? Mol Cell Endocrinol. 2006;248(1-2):3-8. Abstract
Hundertmark S, Dill A, Bühler H, Stevens P, Looman K, Ragosch V, et al. 11beta-hydroxysteroid dehydrogenase type 1: a new regulator of fetal lung maturation. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme. 2002;34:537-44. Abstract
Nair S, Lee YH, Lindsay RS, Walker BR, Tataranni PA, Bogardus C, et al. 11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia. 2004;47:1088-95. Abstract
Chapman KE, Gilmour JS, Coutinho AE, Savill JS, Seckl JR. 11Beta-hydroxysteroid dehydrogenase type 1–a role in inflammation? Molecular and cellular endocrinology. 2006;248:3-8. Abstract